Regenxbio (RGNX) Cash from Operations (2014 - 2025)

Regenxbio's Cash from Operations history runs 12 years deep, the most recent figure standing at 52290000.0 for Q4 2025.

• In Q4 2025, Cash from Operations fell 65.35% year-over-year to 52290000.0; the TTM figure through Dec 2025 stood at 123963000.0 (up 28.4% YoY), while the FY2025 annual figure was 123963000.0, up 28.4% from the prior year.
• Cash from Operations was 52290000.0 for Q4 2025 at Regenxbio, up from 55960000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 341497000.0 in Q4 2021 to a low of 80918000.0 in Q1 2023.
• Historically, Cash from Operations has averaged 25205400.0 across 5 years, with a median of 46409500.0 in 2023.
• The sharpest annual moves came in 2021 and 2022: Cash from Operations soared 765.25% in 2021, then tumbled 111.53% in 2022.
• A 5-year view of Cash from Operations shows it stood at 341497000.0 in 2021, then sank by 111.53% to 39372000.0 in 2022, then decreased by 3.53% to 40760000.0 in 2023, then advanced by 22.41% to 31624000.0 in 2024, then sank by 65.35% to 52290000.0 in 2025.
• The last three Cash from Operations figures came in at 52290000.0 (Q4 2025), 55960000.0 (Q3 2025), and 49342000.0 (Q2 2025), per Business Quant data.